Abstract：
UNASSIGNED: Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.
UNASSIGNED: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.
UNASSIGNED: The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
UNASSIGNED: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.
UNASSIGNED: The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
摘要：
■肥胖，以异常的脂肪积累为标志，构成重大健康风险，需要有效的治疗干预措施。本综述的重点是阐明胰高血糖素样肽1（GLP-1）受体结合药物在解决肥胖相关健康恶化中的重要性。
■探索机制，功效,和安全概况，这篇综述全面评估了选择性或非选择性结合GLP-1受体的药物治疗肥胖的疗效.对第二阶段和第三阶段数据位置retatrutide进行了细致的分析，CagriSema,survudotide,泰西帕肽,塞马鲁肽,和利拉鲁肽的有效性顺序。在展示其功效和安全性的同时，审查承认正在进行的第三阶段研究，强调需要进一步探索禁忌症，剂量,和潜在的不利影响，以告知个性化的治疗决策。
■对长期利益的持续预期，特别是持续的体重减轻和心血管结局，强调了未来治疗算法对解决肥胖症的重要性。
■探索机制，功效,和安全概况，这篇综述全面评估了选择性或非选择性结合GLP-1受体的药物治疗肥胖的疗效.对第二阶段和第三阶段数据位置retatrutide进行了细致的分析，CagriSema,survudotide,泰西帕肽,塞马鲁肽,和利拉鲁肽的有效性顺序。在展示其功效和安全性的同时，审查承认正在进行的第三阶段研究，强调需要进一步探索禁忌症，剂量,和潜在的不利影响，以告知个性化的治疗决策。
■对长期利益的持续预期，特别是持续的体重减轻和心血管结局，强调了未来治疗算法对解决肥胖症的重要性。
